(COTY) Coty - Overview
Stock: Fragrances, Color Cosmetics, Skin Care
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 92.6% |
| Relative Tail Risk | -5.92% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.53 |
| Alpha | -77.01 |
| Character TTM | |
|---|---|
| Beta | 1.047 |
| Beta Downside | 0.737 |
| Drawdowns 3y | |
|---|---|
| Max DD | 79.94% |
| CAGR/Max DD | -0.46 |
Description: COTY Coty January 10, 2026
Coty Inc. (NYSE:COTY) manufactures, markets, distributes, and sells branded beauty products worldwide through two operating segments: Prestige (high-end fragrances and cosmetics) and Consumer Beauty (mass-market makeup, skin-care, and fragrance).
The Prestige portfolio includes luxury licenses such as Burberry, Gucci, and Kylie Cosmetics, sold via perfumeries, department stores, e-retailers, direct-to-consumer sites, and duty-free locations. The Consumer Beauty segment covers mass-market brands like CoverGirl, Rimmel, and Sally Hansen, distributed through hypermarkets, drug stores, pharmacies, and online retailers, as well as third-party distributors.
Founded in 1904 and headquartered in New York, Coty operates as a subsidiary of JAB Beauty B.V., a private-equity-backed holding company that also owns other personal-care brands.
Key recent metrics (FY 2023): revenue of approximately $5.6 billion, adjusted EBITDA margin of ~8 %, and net debt of about $3.5 billion. The company has been accelerating digital-first initiatives and cost-efficiency programs, which aligns with broader sector drivers such as rising e-commerce penetration, shifting consumer spending toward premium-beauty experiences, and strong growth in emerging-market disposable income.
For a deeper quantitative assessment, consider reviewing Coty’s valuation and risk metrics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -382.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 0.60 > 1.0 |
| NWC/Revenue: -6.43% < 20% (prev -6.57%; Δ 0.14% < -1%) |
| CFO/TA 0.04 > 3% & CFO 490.4m > Net Income -382.9m |
| Net Debt (4.03b) to EBITDA (273.0m): 14.77 < 3 |
| Current Ratio: 0.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (876.3m) vs 12m ago 0.11% < -2% |
| Gross Margin: 64.55% > 18% (prev 0.65%; Δ 6390 % > 0.5%) |
| Asset Turnover: 47.19% > 50% (prev 49.12%; Δ -1.93% > 0%) |
| Interest Coverage Ratio: -0.63 > 6 (EBITDA TTM 273.0m / Interest Expense TTM 218.2m) |
Altman Z'' -2.46
| A: -0.03 (Total Current Assets 2.17b - Total Current Liabilities 2.55b) / Total Assets 12.06b |
| B: -0.43 (Retained Earnings -5.20b / Total Assets 12.06b) |
| C: -0.01 (EBIT TTM -137.3m / Avg Total Assets 12.29b) |
| D: -0.74 (Book Value of Equity -5.91b / Total Liabilities 8.00b) |
| Altman-Z'' Score: -2.46 = D |
Beneish M -3.02
| DSRI: 1.14 (Receivables 755.1m/703.5m, Revenue 5.80b/6.15b) |
| GMI: 1.01 (GM 64.55% / 64.93%) |
| AQI: 1.00 (AQ_t 0.74 / AQ_t-1 0.74) |
| SGI: 0.94 (Revenue 5.80b / 6.15b) |
| TATA: -0.07 (NI -382.9m - CFO 490.4m) / TA 12.06b) |
| Beneish M-Score: -3.02 (Cap -4..+1) = AA |
What is the price of COTY shares?
Over the past week, the price has changed by -16.09%, over one month by -16.09%, over three months by -28.49% and over the past year by -61.17%.
Is COTY a buy, sell or hold?
- StrongBuy: 7
- Buy: 1
- Hold: 10
- Sell: 2
- StrongSell: 0
What are the forecasts/targets for the COTY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.5 | 67.7% |
| Analysts Target Price | 4.5 | 67.7% |
| ValueRay Target Price | 2.1 | -21.8% |
COTY Fundamental Data Overview February 03, 2026
P/S = 0.4781
P/B = 0.7466
P/EG = 0.1783
Revenue TTM = 5.80b USD
EBIT TTM = -137.3m USD
EBITDA TTM = 273.0m USD
Long Term Debt = 4.02b USD (from longTermDebt, last quarter)
Short Term Debt = 66.7m USD (from shortTermDebt, last quarter)
Debt = 4.30b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.03b USD (from netDebt column, last quarter)
Enterprise Value = 6.81b USD (2.77b + Debt 4.30b - CCE 264.6m)
Interest Coverage Ratio = -0.63 (Ebit TTM -137.3m / Interest Expense TTM 218.2m)
EV/FCF = 22.78x (Enterprise Value 6.81b / FCF TTM 298.7m)
FCF Yield = 4.39% (FCF TTM 298.7m / Enterprise Value 6.81b)
FCF Margin = 5.15% (FCF TTM 298.7m / Revenue TTM 5.80b)
Net Margin = -6.60% (Net Income TTM -382.9m / Revenue TTM 5.80b)
Gross Margin = 64.55% ((Revenue TTM 5.80b - Cost of Revenue TTM 2.06b) / Revenue TTM)
Gross Margin QoQ = 64.47% (prev 62.26%)
Tobins Q-Ratio = 0.56 (Enterprise Value 6.81b / Total Assets 12.06b)
Interest Expense / Debt = 1.20% (Interest Expense 51.6m / Debt 4.30b)
Taxrate = 30.91% (33.1m / 107.1m)
NOPAT = -94.9m (EBIT -137.3m * (1 - 30.91%)) [loss with tax shield]
Current Ratio = 0.85 (Total Current Assets 2.17b / Total Current Liabilities 2.55b)
Debt / Equity = 1.14 (Debt 4.30b / totalStockholderEquity, last quarter 3.79b)
Debt / EBITDA = 14.77 (Net Debt 4.03b / EBITDA 273.0m)
Debt / FCF = 13.50 (Net Debt 4.03b / FCF TTM 298.7m)
Total Stockholder Equity = 3.76b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.12% (Net Income -382.9m / Total Assets 12.06b)
RoE = -10.19% (Net Income TTM -382.9m / Total Stockholder Equity 3.76b)
RoCE = -1.76% (EBIT -137.3m / Capital Employed (Equity 3.76b + L.T.Debt 4.02b))
RoIC = -1.28% (negative operating profit) (NOPAT -94.9m / Invested Capital 7.41b)
WACC = 4.34% (E(2.77b)/V(7.07b) * Re(9.77%) + D(4.30b)/V(7.07b) * Rd(1.20%) * (1-Tc(0.31)))
Discount Rate = 9.77% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -2.55%
[DCF Debug] Terminal Value 85.23% ; FCFF base≈273.4m ; Y1≈246.4m ; Y5≈211.8m
Fair Price DCF = 2.71 (EV 6.40b - Net Debt 4.03b = Equity 2.37b / Shares 874.6m; r=5.90% [WACC]; 5y FCF grow -12.25% → 2.90% )
EPS Correlation: -25.14 | EPS CAGR: -10.52% | SUE: -4.0 | # QB: 0
Revenue Correlation: 25.02 | Revenue CAGR: -0.02% | SUE: 0.01 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.07 | Chg30d=+0.002 | Revisions Net=+2 | Analysts=13
EPS current Year (2026-06-30): EPS=0.43 | Chg30d=+0.006 | Revisions Net=-2 | Growth EPS=+94.4% | Growth Revenue=-0.4%
EPS next Year (2027-06-30): EPS=0.48 | Chg30d=-0.002 | Revisions Net=+1 | Growth EPS=+13.0% | Growth Revenue=+2.4%